Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 662 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems November 9, 2018 EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Holidays, Traditions and Grief December 21, 2020 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Load more HOT NEWS Though the Pandemic Has Slowed, Many Are Still Struggling to Put... How People With Advanced Cancer Can Find Meaning Toward the End... Help Desk for Oncologists Treating People with a Rare Leukemia Pays... ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned...
